SCHEMBL27218817

SCHEMBL27218817

Cc1cc(N)nc(SCc2nc(CC(C)C)no2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.50
▸ LMNA P02545 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ ALDH1A1 P00352 5/20 0.36
▸ ATM Q13315 1/20 0.36
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ CYP2C19 P33261 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218782 0.84 RAB9A (0.47) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL31528335 0.82 RAB9A (0.50) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL27218748 0.82 RAB9A (0.50) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL27218708 0.81 RAB9A (0.49) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL31494455 0.78 RAB9A (0.48) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL31494410 0.77 RAB9A (0.52) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL27218673 0.75 RAB9A (0.46) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL27218745 0.75 RAB9A (0.50) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL31494430 0.74 SMN1; SMN2 (0.72) RAB9ALMNANPC1SMN1; SMN2HTT
SCHEMBL31494451 0.73 RAB9A (0.48) RAB9ALMNANPC1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RAB9A 2474/4885LMNA 3526/4885NPC1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback